OncoMatch/Clinical Trials/NCT05514275

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Is NCT05514275 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Endostatin and Capecitabine for nasopharyngeal carcinoma.

Phase 2RecruitingZhejiang Cancer HospitalNCT05514275Data as of May 2026

Treatment: Endostatin and Capecitabine — Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage T3-4N1, N2-3 (8th American Joint Commission on Cancer edition)

Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition). No evidence of distant metastasis (M0).

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Must have received: neoadjuvant chemotherapy — neoadjuvant

unsatisfactory tumor response (stable or progressive disease) after neoadjuvant chemotherapy (NACT)

Cannot have received: chemotherapy

Exception: except neoadjuvant chemotherapy

Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes

Cannot have received: surgery

Exception: except diagnostic

Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes

Cannot have received: radiotherapy

Exception: except for non-melanomatous skin cancers outside intended RT treatment volume

History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)

Lab requirements

Blood counts

leucocyte count ≥4000/μL, hemoglobin ≥90g/L, platelet count ≥100000/μL

Kidney function

creatinine clearance ≥60 ml/min

Liver function

ALT, AST <1.5×ULN; ALP ≤2.5×ULN; bilirubin ≤ULN

Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL. Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN. Adequate renal function: creatinine clearance ≥60 ml/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify